The move follows data from the RECOVERY trial showing no beneficial effect of the drug in patients hospitalised with COVID-19Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.